180 Life Sciences Corp. (ATNF )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ATNF
- Company 180 Life Sciences Corp.
- Price $4.33
- Changes Percentage -33.08
- Change -2.14
- Day Low $3.77
- Day High $4.96
- Year High $17.75
- Year Low $1.16
- Market Cap $4,446,603
- Price Avg 50 EMA (D) $1.86
- Price Avg 200 EMA (D) $2.44
- Exchange NASDAQ
- Volume 3,195,791
- Average Volume 1,458,660
- Open $4.56
- Previous Close $6.47
- EPS -11.2
- PE -0.39
- Earnings Announcement 2024-11-07 00:00:00
- Shares Outstanding $1,026,929
Company brief: 180 LIFE SCIENCES CORP. (ATNF )
- Healthcare
- Biotechnology
- Mr. Lloyd Blair Jordan L.L.B., M.B.A.
- https://180lifesciences.com
- US
- N/A
- 06-27-2017
- US68236V3024
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.